Major trial tests first potential Huntington's Disease-Slowing drug
NCT ID NCT07326709
Summary
This large, late-stage study is testing whether a new drug called votoplam can slow down the progression of Huntington's disease in people who have just started showing symptoms. About 770 participants will receive either the drug or a placebo for up to three years to see if it helps them maintain their thinking, movement, and daily living abilities longer. The main goal is to see if the treatment is safe and if it can delay the worsening of this serious genetic condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Georgetown University
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Email: •••••@•••••
-
Novartis Investigative Site
RECRUITINGMontreal, Quebec, H2W 1T8, Canada
Conditions
Explore the condition pages connected to this study.